News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
289,203 Results
Type
Article (14889)
Company Profile (107)
Press Release (274205)
Multimedia
Podcasts (71)
Webinars (14)
Section
Business (90762)
Career Advice (468)
Deals (15952)
Drug Delivery (82)
Drug Development (38973)
Employer Resources (51)
FDA (6599)
Job Trends (6389)
News (155855)
Policy (14465)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (498)
Accelerated approval (26)
ADA (10)
Adcomms (9)
Allergies (99)
Alliances (23939)
ALS (95)
Alzheimer's disease (740)
Antibody-drug conjugate (ADC) (168)
Approvals (6913)
Artificial intelligence (291)
ASCO (124)
Autoimmune disease (87)
Automation (22)
Bankruptcy (152)
Best Places to Work (4513)
BIOSECURE Act (9)
Biosimilars (153)
Biotechnology (43)
Bladder cancer (52)
Brain cancer (46)
Breast cancer (234)
Cancer (1890)
Cardiovascular disease (204)
Career advice (422)
Career pathing (14)
CAR-T (77)
CDC (7)
Cell therapy (231)
Cervical cancer (20)
Clinical research (34572)
Collaboration (1001)
Commercialization (1)
Company closure (1)
Compensation (448)
Complete response letters (47)
COVID-19 (813)
CRISPR (57)
C-suite (659)
Cystic fibrosis (63)
Data (2927)
Decentralized trials (1)
Denatured (19)
Depression (87)
Dermatology (16)
Diabetes (173)
Diagnostics (1523)
Digital health (16)
Diversity (3)
Diversity, equity & inclusion (14)
Drug discovery (173)
Drug pricing (122)
Drug shortages (15)
Duchenne muscular dystrophy (114)
Earnings (35472)
Editorial (25)
Employer branding (4)
Employer resources (47)
Events (42720)
Executive appointments (633)
FDA (8103)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (2)
Frontotemporal dementia (12)
Funding (599)
Gene editing (92)
Generative AI (28)
Gene therapy (252)
GLP-1 (502)
Government (1459)
Grass and pollen (4)
Guidances (177)
Healthcare (4006)
Hematology (71)
HIV (18)
Huntington's disease (17)
IgA nephropathy (52)
Immunology and inflammation (90)
Immuno-oncology (32)
Indications (103)
Infectious disease (917)
Inflammatory bowel disease (91)
Inflation Reduction Act (7)
Influenza (29)
Intellectual property (146)
Interviews (60)
IPO (6267)
IRA (33)
Job creations (2079)
Job search strategy (375)
JPM (31)
Kidney cancer (12)
Labor market (36)
Layoffs (216)
Leadership (10)
Legal (3489)
Liver cancer (26)
Longevity (10)
Lung cancer (287)
Lymphoma (173)
Machine learning (17)
Management (18)
Manufacturing (571)
Marketing (1)
MASH (92)
Medical affairs (1)
Medical device (1397)
Medtech (1412)
Mergers & acquisitions (10242)
Metabolic disorders (589)
mRNA (67)
Multiple sclerosis (103)
NASH (15)
Neurodegenerative disease (169)
Neuropsychiatric disorders (70)
Neuroscience (1530)
Neurotech (1)
NextGen: Class of 2026 (1688)
Non-profit (650)
Now hiring (24)
Obesity (304)
Opinion (158)
Ovarian cancer (65)
Pain (141)
Pancreatic cancer (74)
Parkinson's disease (167)
Partnered (12)
Patents (306)
Patient recruitment (202)
Peanut (15)
People (30838)
Pharmaceutical (62)
Pharmacy benefit managers (19)
Phase 1 (9230)
Phase 2 (14765)
Phase 3 (12917)
Pipeline (3847)
Policy (148)
Postmarket research (1435)
Preclinical (3753)
Press Release (26)
Prostate cancer (114)
Psychedelics (30)
Radiopharmaceuticals (167)
Rare diseases (516)
Real estate (2742)
Recruiting (19)
Regulatory (11788)
Reports (16)
Research institute (613)
Resumes & cover letters (56)
Rett syndrome (23)
RNA editing (11)
RSV (26)
Schizophrenia (113)
Series A (121)
Series B (73)
Service/supplier (2)
Sickle cell disease (57)
Special edition (11)
Spinal muscular atrophy (97)
Sponsored (15)
Startups (1703)
State (2)
Stomach cancer (6)
Supply chain (65)
Tariffs (72)
The Weekly (50)
Vaccines (278)
Venture capital (42)
Weight loss (175)
Women's health (49)
Worklife (4)
Date
Today (36)
Last 7 days (201)
Last 30 days (1007)
Last 365 days (11303)
2026 (5706)
2025 (11623)
2024 (13520)
2023 (15380)
2022 (20736)
2021 (21274)
2020 (19914)
2019 (15789)
2018 (12295)
2017 (14330)
2016 (13534)
2015 (15964)
2014 (12755)
2013 (10773)
2012 (11559)
2011 (12091)
2010 (11037)
Location
Africa (326)
Alabama (23)
Alaska (1)
Arizona (91)
Arkansas (4)
Asia (22030)
Australia (2887)
California (4258)
Canada (1828)
China (802)
Colorado (181)
Connecticut (164)
Delaware (174)
Europe (43071)
Florida (855)
Georgia (83)
Hawaii (1)
Idaho (13)
Illinois (483)
India (66)
Indiana (317)
Iowa (2)
Japan (362)
Kansas (84)
Kentucky (22)
Louisiana (12)
Maine (2)
Maryland (550)
Massachusetts (3659)
Michigan (55)
Minnesota (205)
Mississippi (1)
Missouri (38)
Montana (10)
Nebraska (8)
Nevada (22)
New Hampshire (9)
New Jersey (1859)
New Mexico (8)
New York (1458)
North Carolina (758)
North Dakota (3)
Northern California (2018)
Ohio (102)
Oklahoma (6)
Oregon (19)
Pennsylvania (908)
Puerto Rico (18)
Rhode Island (19)
South America (513)
South Carolina (11)
Southern California (1869)
Tennessee (67)
Texas (664)
United States (17244)
Utah (68)
Vermont (1)
Virginia (210)
Washington D.C. (42)
Washington State (309)
West Virginia (1)
Wisconsin (52)
Wyoming (1)
289,203 Results for "cns pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Lynk Pharmaceuticals’ Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor
June 9, 2026
·
3 min read
Press Releases
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
May 4, 2026
·
6 min read
Press Releases
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
May 14, 2026
·
6 min read
Press Releases
Formation Bio Doses First Participant in Phase 1 Trial of BLKR201, a CNS-Penetrant TYK2 Inhibitor
June 9, 2026
·
3 min read
Press Releases
Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical
June 12, 2026
·
3 min read
Press Releases
CNS Pharmaceuticals CFO, Steve O’Loughlin, Highlights Company’s Recent $22.5M Financing in Virtual Investor “What This Means” Segment
June 8, 2026
·
3 min read
Press Releases
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company’s Recent Strategic Transformation Progress
May 20, 2026
·
3 min read
Press Releases
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
March 13, 2026
·
1 min read
Press Releases
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
March 11, 2026
·
1 min read
Press Releases
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
April 28, 2026
·
7 min read
1 of 28,921
Next
